Table 2. Anti-HBs seropositivity rates, percentage of subjects with antibody concentrations ≥ 10 mIU/ml and GMCs at the pre- and post-challenge dose time-point (long-term ATP cohort for immunogenicity) in the groups boosted and unboosted at year 5.
| Group |
Time point |
N |
S+ |
≥ 10 mIU/ml |
GMC* mIU/ml |
|||
|---|---|---|---|---|---|---|---|---|
| % | 95% CI | % | 95% CI | mIU/ml | 95% CI | |||
| Boosted at year 5 |
Pre |
14 |
92.9 |
(66.1,99.8) |
71.4 |
(41.9,91.6) |
33.1 |
(15.2,72.0) |
| |
Post |
14 |
100 |
(76.8,100) |
100 |
(76.8,100) |
2115.4 |
(1053.6,4247.3) |
| Unboosted at year 5 |
Pre |
29 |
75.9 |
(56.5,89.7) |
44.8 |
(26.4,64.3) |
14.5 |
(10.0,21.2) |
| Post | 29 | 100 | (88.1,100) | 96.6 | (82.2,99.9) | 296.3 | (129.1,680.4) | |
N, number of subjects with available results; %, percentage of subjects with antibody concentrations ≥ the specified cut-off; GMC*, geometric mean antibody concentration calculated on subjects with antibody concentrations ≥ 3.3 mIU/ml; 95% CI: 95% confidence interval; PRE, blood sampling at the last available time-point; POST, blood sampling post-challenge dose